MA46611A - Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs - Google Patents

Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs

Info

Publication number
MA46611A
MA46611A MA046611A MA46611A MA46611A MA 46611 A MA46611 A MA 46611A MA 046611 A MA046611 A MA 046611A MA 46611 A MA46611 A MA 46611A MA 46611 A MA46611 A MA 46611A
Authority
MA
Morocco
Prior art keywords
psychiatric
treatment
cognitive disorders
combination treatments
imidazopyrazinones
Prior art date
Application number
MA046611A
Other languages
English (en)
Other versions
MA46611B1 (fr
Inventor
Mikkel Jessing
Karsten Juhl
Jan Kehler
Morten Langgård
Lars Kyhn Rasmussen
Paulo Jorge Vieira Vital
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA46611A publication Critical patent/MA46611A/fr
Publication of MA46611B1 publication Critical patent/MA46611B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des traitements combinés comprenant l'administration de composés qui sont des inhibiteurs d'enzyme pde1 et d'autres composés utiles dans le traitement de troubles psychiatriques et/ou cognitifs tels que, par exemple, le trouble du déficit de l'attention avec hyperactivité (tdah), la dépression, l'anxiété, la narcolepsie, la schizophrénie, la déficience cognitive ou la déficience cognitive associée à la schizophrénie (cias, pour "cognitive impairment associated with schizophrenia"). Des aspects séparés de l'invention concernent l'utilisation combinée desdits composés pour le traitement de troubles psychiatriques et/ou cognitifs. La présente invention concerne également des compositions pharmaceutiques comprenant lesdits inhibiteurs d'enzyme pde1 conjointement avec d'autres composés utiles dans le traitement de troubles psychiatriques et/ou cognitifs.
MA46611A 2016-10-28 2017-10-26 Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs MA46611B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600659 2016-10-28
PCT/EP2017/077497 WO2018078038A1 (fr) 2016-10-28 2017-10-26 Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs

Publications (2)

Publication Number Publication Date
MA46611A true MA46611A (fr) 2019-09-04
MA46611B1 MA46611B1 (fr) 2020-08-31

Family

ID=60186299

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46611A MA46611B1 (fr) 2016-10-28 2017-10-26 Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs

Country Status (30)

Country Link
US (1) US10905688B2 (fr)
EP (1) EP3532064B1 (fr)
JP (1) JP2019536762A (fr)
KR (1) KR20190075068A (fr)
CN (1) CN109803658A (fr)
AR (1) AR109991A1 (fr)
AU (1) AU2017350473A1 (fr)
BR (1) BR112018013247A2 (fr)
CA (1) CA3041607A1 (fr)
CL (1) CL2019001091A1 (fr)
CO (1) CO2019002909A2 (fr)
CY (1) CY1123396T1 (fr)
DK (1) DK3532064T3 (fr)
ES (1) ES2816005T3 (fr)
HR (1) HRP20201326T1 (fr)
HU (1) HUE050403T2 (fr)
IL (1) IL265635A (fr)
LT (1) LT3532064T (fr)
MA (1) MA46611B1 (fr)
ME (1) ME03821B (fr)
MX (1) MX2019004763A (fr)
PL (1) PL3532064T3 (fr)
PT (1) PT3532064T (fr)
RS (1) RS60716B1 (fr)
RU (1) RU2019109039A (fr)
SG (1) SG11201903770UA (fr)
SI (1) SI3532064T1 (fr)
SM (1) SMT202000440T1 (fr)
WO (1) WO2018078038A1 (fr)
ZA (1) ZA201902091B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3529250B1 (fr) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
US10905688B2 (en) 2016-10-28 2021-02-02 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
CA3041595A1 (fr) 2016-10-28 2018-05-03 H. Lundbeck A/S Traitements combines comprenant l'administration d'imidazopyrazinones
SG11202006916SA (en) 2018-02-01 2020-08-28 Japan Tobacco Inc Nitrogenated heterocyclic amide compound, and use thereof for medical purposes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
JP2006525966A (ja) 2003-05-09 2006-11-16 バイエル・ヘルスケア・アクチェンゲゼルシャフト ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007025103A2 (fr) 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Composes organiques
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (fr) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Nouvelles utilisations
ES2377849T3 (es) 2007-05-11 2012-04-02 Pfizer Inc. Compuestos amino-heterocíclicos
EP2227472A1 (fr) 2007-11-30 2010-09-15 Elbion Gmbh Imidazoý1,5-a¨pyrazines fusionnées à aryle et hétéroaryle comme inhibiteur de la phosphodiestérase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2736304A1 (fr) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines et leur utilisation pour le traitement de troubles du snc
JP5813511B2 (ja) 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CN102596221B (zh) 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
WO2011153136A1 (fr) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Composés organiques
LT3042917T (lt) 2010-08-12 2018-05-10 Eli Lilly And Company Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas
RU2603140C2 (ru) 2010-09-20 2016-11-20 Айронвуд Фармасьютикалз, Инк. Соединения имидазотриазинона
WO2012040048A2 (fr) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones comme antagonistes des récepteurs p2x7
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
WO2012171016A1 (fr) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Composés organiques
JP2015531401A (ja) * 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
MX351582B (es) 2012-01-26 2017-10-20 H Lundbeck As Inhibidores de pde9 con estructura basica de imidazotriazinona.
RU2659779C2 (ru) 2012-06-18 2018-07-04 Дарт Нейросайенс (Кайман) Лтд Замещенные соединения тиофен- и фуран-конденсированного азолопиримидин-5-(6н)-она
JP6437519B2 (ja) 2013-03-15 2018-12-12 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
GEP20186892B (en) 2014-02-19 2018-09-10 Lundbeck A/S H 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20170273985A1 (en) 2014-09-18 2017-09-28 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
WO2016147659A1 (fr) 2015-03-16 2016-09-22 Sumitomo Dainippon Pharma Co., Ltd. Dérivé imidazolo bicyclique
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
TN2018000035A1 (en) 2015-08-12 2019-07-08 H Lundbeck As 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
CN105254635A (zh) * 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
EP3529250B1 (fr) 2016-10-18 2023-12-06 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones et pyrazolopyridinones en tant qu'inhibiteurs de pde1
US10905688B2 (en) 2016-10-28 2021-02-02 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
CA3041595A1 (fr) 2016-10-28 2018-05-03 H. Lundbeck A/S Traitements combines comprenant l'administration d'imidazopyrazinones

Also Published As

Publication number Publication date
ZA201902091B (en) 2020-10-28
CL2019001091A1 (es) 2019-07-05
HUE050403T2 (hu) 2020-12-28
RS60716B1 (sr) 2020-09-30
WO2018078038A1 (fr) 2018-05-03
DK3532064T3 (da) 2020-08-24
BR112018013247A2 (pt) 2018-12-04
ES2816005T3 (es) 2021-03-31
MA46611B1 (fr) 2020-08-31
SI3532064T1 (sl) 2020-10-30
CY1123396T1 (el) 2021-12-31
ME03821B (fr) 2021-04-20
CA3041607A1 (fr) 2018-05-03
AU2017350473A1 (en) 2019-04-18
IL265635A (en) 2019-05-30
RU2019109039A (ru) 2020-11-30
JP2019536762A (ja) 2019-12-19
US10905688B2 (en) 2021-02-02
CN109803658A (zh) 2019-05-24
PL3532064T3 (pl) 2020-11-16
SG11201903770UA (en) 2019-05-30
SMT202000440T1 (it) 2020-09-10
LT3532064T (lt) 2020-09-25
RU2019109039A3 (fr) 2021-01-29
AR109991A1 (es) 2019-02-13
EP3532064B1 (fr) 2020-07-29
PT3532064T (pt) 2020-09-03
HRP20201326T1 (hr) 2020-11-27
CO2019002909A2 (es) 2019-06-19
EP3532064A1 (fr) 2019-09-04
MX2019004763A (es) 2019-07-01
US20190282571A1 (en) 2019-09-19
KR20190075068A (ko) 2019-06-28

Similar Documents

Publication Publication Date Title
MA46611A (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
MA40290A1 (fr) Agents immunorégulateurs
MA54231A (fr) Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA52288B1 (fr) Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci
WO2019035864A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA38261A1 (fr) Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc)
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA43756B1 (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
TNSN07258A1 (fr) Derives de quinoleine heteroaromatiques et leur utilisation comme inhibiteurs de pde10
MA58049B1 (fr) Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA41757A (fr) Transplantation ciblée de mitochondries dans des hépatocytes
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA30037B1 (fr) Compositions et procedes destines au traitement des troubles du snc
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques